When was Zumutor founded?

Zumutor was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Zumutor located?

Zumutor is headquartered in Cambridge, United States.

Which legal entities is Zumutor associated with?

Zumutor is associated with ZUMUTOR BIOLOGICS PRIVATE LIMITED and 1 other.

How many employees does Zumutor have?

As of Feb 28, 2025, the latest employee count at Zumutor is 19.

Is Zumutor a funded company?

Zumutor is a funded company, having raised a total of $35.2M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2013.

How much is Zumutor worth?

The latest valuation of Zumutor is ₹***** as of Jun 13, 2026.

When was the latest funding round of Zumutor?

Zumutor's latest funding was a $***** Series B round on Jun 13, 2026, with participation from 4 investors.

What is the annual revenue of Zumutor?

Annual revenue of Zumutor is less than ₹10 Cr as on Mar 31, 2025

Where does Zumutor rank among its competitors?

Zumutor ranks 382nd amongst 3468 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Zumutor, which secured $7.3M in Jun, 2026.

Who are the top competitors of Zumutor?

Zumutor's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Zumutor secured the most recent funding round in June, 2026.

Zumutor - 2026 Company Profile, Team, Funding, Competitors & Financials

Zumutor is a series B company based in Cambridge (United States), founded in 2013 by Sohang Chatterjee. It operates as a Developer of novel immunotherapy and monoclonal antibody therapeutics. Zumutor has raised $35.2M in funding from investors like Accel, Bharat Innovation Fund and Siana Capital, with a current valuation of ₹*****. The company has 3468 active competitors, including 1140 funded and 795 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of novel immunotherapy and monoclonal antibody therapeutics. This company utilizes a proprietary human antibody platform to identify and develop first-in-class therapeutic antibodies. These antibodies target innate immunity and modulate the tumor microenvironment, focusing on targeted NK cell therapeutics within the immuno-oncology field. The company's approach centers on a platform for developing improved monoclonal antibody therapeutics. They maintain a commitment to scientific talent development within therapeutic research and development.

Website: zumutor.com
Social
Email ID: *****@zumutor.com, *****@zumutor.com
Phone Number: +91 **********

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Series B

Total Funding

$35.2M in 9 rounds

Latest Funding Round

Series B, Jun 13, 2026, $*****

Post Money Valuation

₹***** as on Jun 13, 2026

Investors

Accel & 20 more

Ranked

382^nd among 3468 active competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2025

Employee Count

19 as on Feb 28, 2025

Similar Companies

BeiGene & 773 more

View Zumutor's full profile

Zumutor is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Zumutor Biologics Inc. CIN: 5769405 , United States, Active	Jun 18, 2015	-	30 (As on May 31, 2022)	-
ZUMUTOR BIOLOGICS PRIVATE LIMITED CIN: U73200KA2015FTC081944 , India, Active	Jul 31, 2015	0 - ₹10 Cr (As on Mar 31, 2025)	19 (As on Apr 01, 2026)

Zumutor has raised a total funding of $35.2M over 9 rounds. Its first funding round was on 2013. Its latest funding round was a Series B round on Jun 13, 2026 for $*****. 4 investors participated in its latest round. Zumutor has 15 institutional investors and 6 angel investors.

Here is the list of recent funding rounds of Zumutor:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 13, 2026	5664493	Series B	4771019	8782651	3998121	2686839
Nov 27, 2024	5853578	Series A	5176529	2069839	9283147	9076481
Feb 20, 2024	3508132	Series A	7579624	1270375	Bharat Innovation Fund	1720215

Access funding benchmarks and valuations. Sign up today!

View details of Zumutor's funding rounds and investors

The founders of Zumutor is Sohang Chatterjee.

Here are the details of Zumutor's key team members:

Sohang Chatterjee: Former Co-Founder of Zumutor and founder of 1 other company. They serve on the board of 1 company.

Zumutor's Board of Directors

Zumutor's board has 2 active members. Maloy Ghosh is part of team and Sunit Maity is independent board member.

Here is the list of Zumutor's board of directors:

Name	Type	Representing	Status	Duration
yndstbx	Team	-	Past	5y 6m
fnie{jd	Team	-	Past	8y 6m
oizsrvi	Independent board member	-	Past	5y 2m

View details of Zumutor's Founder profiles and Board Members

Zumutor's employee count trend

Zumutor has 19 employees as of Feb 25. Here is Zumutor's employee count trend over the years:

Uncover Zumutor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zumutor include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Zumutor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
382nd	Zumutor 2013, Cambridge (United States), Series B	Developer of novel immunotherapy and monoclonal antibody therapeutics	$35.2M	Chiratae Ventures, Premji Invest & 19 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Zumutor's competitors? Click here to see the top ones

ZUMUTOR BIOLOGICS PRIVATE LIMITED, the legal entity associated with Zumutor, generated less than ₹10 Cr in revenue for the financial year ending on Mar 31, 2025. The revenue of ZUMUTOR BIOLOGICS PRIVATE LIMITED has a compounded annual growth rate (CAGR) of -64% in the last 1 year.

Financial Statement Summary

Metrics	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Income Statement
Revenue	3346	8063	1169	9658	7095
Total Sales	1496	9743	5881	2049	6107
Total Expenses	8610	3703	2878	9204	2343
Operating Expenses	5356	2002	9023	2783	5550
Employee Expenses	8166	9050	1916	4526	5235
Operating Income (EBIT)	5999	3461	6774	4265	1547
Interest Expenses	8116	6218	8932	9413	2145
Expenses from other activities	7398	6883	5476	3760	4103
EBITDA	3250	7177	7190	7086	5574
Taxes	2309	2331	6653	3729	8220
Net Profit	7018	2175	2880	1247	6812
Balance Sheet
Assets	9876	6440	9650	7144	4186
Accounts Receivables	3983	8874	9380	9301	4691
Inventory	1753	5226	6550	4703	4156
Liabilities	8161	2327	4244	8185	2269
Total Debt	1584	4877	1136	8766	6691
Accounts Payable	6012	1704	3776	9185	1297
Equities	1240	8128	2132	3686	3733

Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)

Founders own 0.01%, Funds own 15.03%, Parent Entities (largest shareholder) own 83.32% and Angels own 1.66%. The net worth of Zumutor's founders is INR 2.66L as of Apr 30, 2025. The cap table displayed below is for ZUMUTOR BIOLOGICS PRIVATE LIMITED which is the legal entity associated with Zumutor.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	0.01%	2.66L	0	0	0	0
Fund	15.03%	48Cr	2909881	5790908	4541670	3809936
Bharat Innovation Fund	7795178	8908544	6495997	5458264	6037546	5682947
Siana Capital	962	582	261	713	603	862
Parent Entity	83.32%	266Cr	8092187	4286108	7502968	3594007
Angel	1.66%	5.27Cr	7	7	8	4
Anand Suresh Deshpande	0	0	0	0	0	0
Total	100.00%	319Cr	6180712	6584751	4853591	8357253